Introduction
MSM are disproportionally affected by the global HIV epidemic [1] [2] [3] . Based on a survey from 2001 to 2006, the risk of HIV infection in low and middle-income countries was nearly 19 times higher among MSM compared with the general population [4] . African MSM are also at high risk of HIV infection [4] [5] [6] [7] [8] . HIV prevalence among MSM in sub-Saharan Africa was reported to be 3.6-fold higher than the prevalence in the general population [1] . Despite efforts to curb the HIV epidemic, HIV incidence remains high among African MSM [1, 9] . Compared with MSM, transgender women in Africa are at an even higher risk of HIV infection [10] . Antiretroviral therapy (ART) plays an essential role in achieving the '90-90-90' target to end the HIV/AIDS epidemic [11] . In sub-Saharan Africa, 7.5 million people living with HIV were receiving ART by the end of 2012 [12] . However, criminalization and social stigmatization have limited use of HIV prevention interventions and access to HIV treatment among MSM in many regions of sub-Saharan Africa [13] . There is little information about antiretroviral drug use among HIV-infected MSM in Africa. As access to ART increases, the prevalence of HIV drug resistance is rising in sub-Saharan Africa [14] . HIV drug-resistance may lead to ART failure and worse health outcomes, compromising long-term control of the HIV/ AIDS epidemic. There are limited data describing HIV drug resistance among African MSM and transgender women.
Antiretroviral drug testing provides an objective biomedical measure of antiretroviral drug use. We developed a high-throughput assay for antiretroviral drug detection that was used to assess antiretroviral drug use in a large, cross-sectional survey of African adults [15] , and other clinical trials and cohort studies [16] [17] [18] . HIV Prevention Trials Network (HPTN) 075 was a multisite observational cohort study that assessed the feasibility of recruiting and retaining MSM and transgender women, to facilitate future HIV prevention studies in this highrisk population. In this study, we assessed antiretroviral drug use and HIV drug resistance among MSM and transgender women who were screened for participation in HPTN 075.
Methods
Study cohort HPTN 075 screened MSM and transgender women at four study sites in three countries (Kisumu, Kenya; Blantyre, Malawi; Soweto and Cape Town, South Africa). Participants included in this analysis met the following study criteria: age 18-44 years, male sex assigned at birth, ever having had sex with a man, willingness to be tested for HIV infection, and confirmed HIV infection at screening.
A subset of the participants described in this study was subsequently enrolled in the HPTN 075 study. HPTN 075 enrolled both HIV-infected and HIV-uninfected MSM and transgender women (age 18-44) who reported anal sex in the past 3 months. HIV-infected participants were excluded from enrollment in HPTN 075 if they reported that they were in HIV care or had been prescribed ART. Study staff was instructed not to disclose the enrollment criteria to the participants during the screening visit.
Laboratory testing
Participants were tested for HIV infection at the screening visit at study sites using either two HIV rapid tests or one HIV rapid test and one enzyme immunoassay. These tests were performed in parallel; at least one of the two tests was performed in a laboratory. Participants were considered to be HIV infected if both tests were reactive. Additional testing was performed retrospectively at the HPTN Laboratory Center (Baltimore, Maryland) using samples collected at the screening visit. This included further testing to confirm HIV status, antiretroviral drug testing, HIV resistance testing, and HIV viral load testing.
Antiretroviral testing was performed using a multidrug assay that combines HPLC with high-resolution-mass mass spectrometry in five drug classes, including three nonnucleoside reverse transcriptase inhibitors [NNRTIs, efavirenz (EFV), nevirapine (NVP), and rilpivirine (RPV)], six nucleoside/nucleotide reverse transcriptase inhibitors [NRTIs, abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), stavudine, tenofovir (TFV), and zidovudine], nine protease inhibitors [amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir (NFV), ritonavir, saquinavir, and tipranavir], one integrase strand transfer inhibitor [raltegravir (RAL)], and one C-C chemokine receptor type 5 (CCR5) receptor antagonist [maraviroc (MVC)] [17] . The limit of detection is 2 ng/ ml for six of the 20 drugs (RAL, MVC, NVP, RPV, ABC, and NFV), and 20 ng/ml for the other 14 drugs [17] .
HIV drug resistance testing was performed for the subset of HIV-infected participants who had antiretroviral drugs detected and had a HIV viral load at least 400 copies/ml. This testing was performed using the ViroSeq HIV-1 Genotyping System, v2.0 (Abbott Diagnostics, Des Plaines, Illinois, USA). HIV sequences were submitted to GenBank (accession numbers: MG597249-MG597259).
HIV viral load testing was performed with the RealTime HIV-1 Viral Load Assay (Abbott Molecular, Abbott Park, Illinois, USA). A validated dilution method was used for testing as the volume of plasma available for testing was limited in some cases; this method has a lower limit of quantification of 400 copies/ml HIV RNA. Viral suppression was defined as viral load less than 400 copies/ml.
Statistical analysis
Univariate and multivariate logistic regression were used to analyze the association of antiretroviral drug detection and other factors (SAS, version 9.4; Cary, North Carolina, USA).
Ethical considerations
All study participants provided informed consent for screening for the HPTN 075 study (oral consent in Blantyre, Malawi; written consent at the other study sites). The study was approved by Institutional Review Boards at each site.
Results

Study cohort
In HPTN 075, 624 MSM and transgender women were screened for study participation; 26 did not meet screening criteria and were excluded from analysis. The remaining 598 participants, included 168 from Kisumu, Kenya; 122 from Blantyre, Malawi; 170 from Soweto, South Africa; and 138 from Cape Town, South Africa. Overall, 183 (30.6%) of 598 participants had confirmed HIV infection at screening (Fig. 1) .
Detection of antiretroviral drugs
Plasma samples collected at the screening visit were tested for the presence of antiretroviral drugs. At least one antiretroviral drug was detected in samples from 63 (34.4%) of the 183 HIV-infected participants, including 19 participants Kisumu, 10 from Blantyre, 11 from Cape Town, and 23 from Soweto ( Fig. 1 , Table 1 ). NNRTIs and NRTIs were the only classes of antiretroviral drugs detected (Table 1) . Two NNRTIs were detected (59 were taking EFV; five were taking NVP), and four NRTIs were detected (52 were taking TFV; 31 were taking 3TC; 27 were taking FTC; one was taking ABC). Two or more antiretroviral drugs were detected in 57 (90.5%) of the 63 cases, consistent with use of a multidrug regimen for ART; two of those participants had unusual combinations of antiretroviral drugs that were not consistent with recommended treatment regimens (one had two NNRTIs þ two NRTIs; one had one NNRTI þ three NRTIs). The remaining six participants had a single antiretroviral drug detected (all had EFV detected alone).
Eleven (17.5%) of the 63 participants who had antiretroviral drugs detected were not virally suppressed Antiretroviral drug use and resistance among African MSM Zhang et al. 1303 Fig. 1 . Proportion of participants with different study outcomes. The figure shows a summary of data from the 183 HIV-infected participants who were screened for participation in HIV Prevention Trials Network 075. Antiretroviral drug testing was performed for all 183 participants using samples collected at the screening visit. Sixty-three participants had antiretroviral drugs detected. Eleven of those participants were not virally suppressed (viral load 400 copies/ml); six of the participants who were not virally suppressed had drug-resistant HIV. VL < 400 copies/ml, N ¼ 52
The (HIV viral load 400 copies/ml, Table 1 ). These 11 participants included six from Kisumu, Kenya; one from Blantyre, Malawi; three from Cape Town, South Africa; and one from Soweto, South Africa ( Table 2 ). The median viral load for the 11 participants was 2200 copies/ ml (range: 430-31 650 copies/ml). These 11 cases included four in which EFV was the only antiretroviral drug detected and seven in which two or three antiretroviral drugs were detected (Table 2) .
HIV drug resistance HIV genotyping was performed for the 11 participants who had antiretroviral drugs detected and were not virally suppressed. At least one major drug resistance mutation was detected in six of the 11 cases (Table 2) . One case had NNRTI resistance only (case 9), one case had NRTI resistance only (case 5), and four cases had multiclass resistant HIV (NRTI and NNRTI resistance, cases 4, 6, 7, and 8).
The most frequently detected mutations were M184V/I (N ¼ 5; associated with NRTI resistance) and K103N (N ¼ 3; associated with NNRTI resistance). Two participants had the K65R mutation, which confers resistance to tenofovir disoproxil fumarate, one of the components of Truvada (Gilead Sciences, Inc., Foster City, California, USA), which is used for HIV preexposure prophylaxis.
All five of the participants who had HIV with major NNRTI resistance mutations were taking EFV or NVP. Among the five participants who had HIV with major NRTI resistance mutations, two had 3TC detected, two had 3TC and TFV detected, and one had no NRTIs detected. In seven (63.6%) of the 11 cases, antiretroviral drugs were detected without detection of corresponding resistance mutations ( Table 2 ). Some of these 11 participants were at risk of acquiring HIV resistance to additional antiretroviral drugs over time. Four participants were at risk of acquiring NNRTI resistance (cases 1-3 and 5), and three were at risk of acquiring NRTI resistance (cases 9-11); in these cases, participants were taking NNRTIs (EFVor NVP) or NRTIs (various combinations of 3TC, TFV, and FTC) and were not virally suppressed.
Factors associated with detection of antiretroviral drugs
We next evaluated the association of demographic and behavioral factors with antiretroviral drug use (Table 3) . In a multivariate model, antiretroviral drugs were more frequently detected among participants who reported being engaged in HIV care or any current or prior antiretroviral drug use, compared with those who did not report prior HIV care or antiretroviral drug use (88.5 vs. 9.8%, P < 0.001). antiretroviral drugs were also detected more frequently among participants who were not asked these questions, as they did not report Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Discussion
The current report evaluated antiretroviral drug use, viral suppression, and HIV drug resistance in a cohort of MSM and transgender women with confirmed HIV infection who were screened for participation in a clinical trial. In this cohort, approximately one-third of the participants (34.4%) were taking antiretroviral drugs at the time of study screening. The most common combinations of antiretroviral drugs detected were EFV þ 3TC þ TFV and EFV þ FTC þ TFV. This combination of drugs is consistent with first-line ART regimens in Kenya, Malawi, and South Africa [19] [20] [21] . Four participants had one NNRTI detected with one NRTI, and six had EFV alone detected; six of these 10 participants were not virally suppressed. Failure to detect two NRTIs in these cases may reflect suboptimal adherence to an ART regimen; alternatively, one or both of the NRTIs may not have been detected because of the short half-lives of these drugs. In the cases in which EFV was detected alone, it is also possible that the participants were taking EFV for recreational purposes [22, 23] . Two (3.2%) of the 63 participants in this cohort who were taking antiretroviral drugs had unusual combinations of antiretroviral drugs detected; in contrast, 29 (48.3%) of the men in HPTN 061 who were taking antiretroviral drugs had unusual combinations of drugs detected [16] . This indicates that the African MSM and transgender women recruited for participation in HPTN 075 were more likely to be taking recommended ART regimens than men recruited into HPTN 061, which was conducted at six cities in the United States.
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The frequency of antiretroviral drug use varied among the HPTN 075 study sites. The highest frequency of antiretroviral drug detection was in Kisumu, Kenya, where antiretroviral drugs were detected in 68% of the HIV-infected participants; the frequency ranged from 25 to 37% at the other three study sites. These regional differences may reflect differences in the availability of ART or other factors. Regional differences in ART coverage among MSM have been observed globally, from 2% (Jamaica and Kyrgyzstan) to 73% (Denmark) [24] . In Kenya, the ART coverage among gay men and other MSM was reported to be 69.9% in 2017, which is similar to the coverage reported here (67.9%) [25] . As a result of stigma, discrimination, and criminalization, it has been difficult to determine the proportion of MSM in subSaharan African countries who are HIV infected and on ART [26, 27] . According to a report published in 2015, ART coverage ranged from 0 to 25% among MSM at different sites in Cameroon, which was much lower than the 57% coverage observed in the general population [28] . In Kenya, Malawi, and South Africa, estimated ART coverage among the general population was 64, 66, and 56% in 2016, respectively [29] .
In this study, older age was associated with antiretroviral drug detection. A higher frequency of ART has been reported among older MSM compared with younger men in the United States [30] . Higher rates of ART adherence were also observed in older adults in the United States and other countries [31 -33] . In our study, sexual partner type (men and women vs. men only) was also associated with antiretroviral drug use, but that association was only observed in univariate analysis. Not surprisingly, in our cohort, participants who reported that they were ever engaged in HIV care and/or on ART were more likely to be using antiretroviral drugs. Participants who reported that they were on ART at the time of screening were not eligible for enrollment in HPTN 075. It is notable that 19 of the participants who enrolled in the study were taking antiretroviral drugs, but did not report this to study staff; in these cases, antiretroviral drug use was revealed through retrospective antiretroviral drug testing. These 19 participants represented 27.1% of the 70 HIV-infected participants enrolled in HPTN 075. In seven (36.8%) of the 19 cases, the participants were not virally suppressed; for this reason, HIV viral load would not have been a useful surrogate marker for undisclosed antiretroviral drug use.
Eleven (17.5%) of the 63 participants who were taking antiretroviral drugs at the screening visit were not virally suppressed. More than half (55%) of those participants had drug-resistant HIV, and about one-third (36.3%) had HIV that was resistant to two classes of HIV drugs (multiclass resistance). Furthermore, seven (63.6%) of the 11 participants were at risk of acquiring additional resistance mutations, further limiting their treatment options. One limitation of this study is that the assay used for antiretroviral drug detection only reflects recent antiretroviral drug use, and drugs present at low levels may not be detected. Also, as population sequencing was used to assess HIV drug resistance, low-frequency drug resistance mutations were not detected; low-frequency mutations can impact ART outcomes [34] . For these reasons, the frequencies of antiretroviral drug use and HIV drug resistance reported in this study should be considered to be minimum estimates.
Conclusion
The overall rate of AIDS-related deaths in sub-Saharan Africa dropped 39% between 2005 and 2013 due to the scale-up of ART [35] . However, the impact of ART scale-up may have had less impact on survival among HIV-infected MSM, as they may have been less likely to access HIV care due to stigma, criminalization, or other factors. Only about one-third of the HIV-infected participants who were screened for HPTN 075 were on suppressive ART. Some participants who were not on ART may not have been aware that they were HIV infected [36] . This finding, and our finding that many participants who were taking antiretroviral drugs had drug-resistant HIV, underscores the need for additional interventions for HIV treatment in this high-risk population.
